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Objectives: Many patients with Cushingｷs disease ｪCDｫ require chronic pharmaco､
therapy to contro旭 their hypercortiso旭isms We eva旭uated the efficacy and safety of 
旭ong､acting pasireotide during a 旭ong､term extension study in patients with CDs
Design: Open､旭abe旭 extension to a ゲゴ､month Phase III study of 旭ong､acting pasire､
otide in CD ｪN ┎ ゲズグq NCTグゲザゼジゾグ葦ｫs
Patients: Patients with mean urinary free cortiso旭 ｪmUFCｫ └ upper 旭imit of norma旭 ｪULNｫ 
or receiving c旭inica旭 benefit at core study end cou旭d continue 旭ong､acting pasireotide 
during the extensions
Results: Eighty､one of ゲズグ ｪズジsグ鯵ｫ enro旭旭ed patients entered the extensions Median 
overa旭旭 exposure to pasireotide at study end was ゴザsゾ monthsq ザゾ｠芦ゲ ｪジ芦sゲ鯵ｫ pa､
tients comp旭eted the extension ｪreceived ┕ ゲゴ monthsv treatment during the ex､
tension and cou旭d transit to a separate pasireotide safety studyｫs mUFC was └ULN 
in ジゴ｠芦ゲ ｪズゲsゾ鯵ｫp ゲザ｠芦ゲ ｪゲ葦sグ鯵ｫ and ジザ｠芦ゲ ｪズザsゲ鯵ｫ patients at extension base旭inep 
month ｪMｫ ザ葦 and 旭ast assessments Median mUFC remained within norma旭 旭imitss 
Median 旭ate､night sa旭ivary cortiso旭 was ゴs葦 ┌ ULN at core base旭ine and ゲsザ ┌ ULN at 
Mザ葦s C旭inica旭 improvements were sustained over times Forty､two ｪズゲsゾ鯵ｫ patients 
discontinued during the extensionr ゴズ ｪザグsゾ鯵ｫ before Mゴジ and ゲゼ ｪゴゲsグ鯵ｫ after Mゴジs 
Hyperg旭ycaemia､re旭ated AEs occurred in ザゾsズ鯵 of patientss Mean fasting g旭ucose 
ｪFPGｫ and g旭ycated haemog旭obin ｪHbA1cｫ were stab旭e during the extensionp with an､
tidiabetic medication initiated｠esca旭ated in some patientss Sixty､six ｪ芦ゲsズ鯵ｫ and ゼゲ 
ｪ芦芦sゾ鯵ｫ patients were c旭assified as having diabetes ｪHbA1c ┕ 葦sズ鯵p FPG ┕ ゼsグ mmo旭｠Lp 
antidiabetic medication usep or history of diabetesｫ at extension base旭ine and 旭ast 
assessments
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ゲ科 |科INTRODUC TION
Cushingｷs disease ｪCDｫ is a rare endocrine disorder characterized by 
overproduction of cortiso旭 by the adrena旭 g旭andsp secondary to an 
adrenocorticotropic hormone ｪACTHｫ･secreting pituitary adenoma 
ｪcorticotropinomaｫs1 CD is associated with significant mu旭tisystem 
morbidityp impaired qua旭ity of 旭ife ｪQoLｫ and increased morta旭ity if 
inadequate旭y treatedsゴpザ
Se旭ective resection of the corticotropinoma by transsphenoida旭 
surgery is the first､choice treatment for CDp but surgica旭 success 
rates vary and depend on the expertise of the surgeons CD persists 
in ゲグ鯵､ザズ鯵 of patients after surgerypジpズ whi旭e recurrence rates range 
from ゲズ鯵 to 葦葦鯵 after a variab旭e duration of remissions葦､芦 Medical 
therapy p旭ays a prominent ro旭e in the management of persistent or 
recurrent CDp as we旭旭 as in patients who are not candidates for sur､
geryp such as those considered to be at high surgica旭 risk and｠or with 
acute comp旭ications of CDsゴp芦､ゲグ
Given the chronic nature of CDp many patients require 旭ong､term 
pharmacotherapy to achieve and maintain the goa旭s of treatmentr to 
contro旭 cortiso旭 excessp reverse c旭inica旭 features and comp旭ications of 
hypercortiso旭ismp improve QoLp contro旭 tumour mass and increase 
旭ife expectancys8 A comprehensive understanding of the 旭ong､term 
efficacy and safety of avai旭ab旭e medica旭 treatment options is there､
fore centra旭 to achieving optima旭 outcomes for patientss
Based on the resu旭ts of a ゲゴ､month Phase III studyp11 a 旭ong､act､
ing intramuscu旭ar formu旭ation of pasireotide suitab旭e for month旭y ad､
ministration has been approved in the EUp United States and other 
countries wor旭dwide for the treatment of CDsゲゴpゲザ Herep we report 
the efficacy and safety of 旭ong､acting pasireotide during a 旭ong､term 




This was an optiona旭p open､旭abe旭 extension to a ゲゴ､month Phase III 
core studys11 Patients cou旭d enter the extension if they satisfied the 
fo旭旭owing criteria at the end of the core studyr mean urinary free corti､
so旭 ｪmUFCq mean of three ゴジ､hour samp旭es co旭旭ected within ゴ weeksｫ 
not exceeding the upper 旭imit of norma旭 ｪULNq ゲ葦葦sズ nmo旭｠ゴジ hｫ and｠
or considered by the investigator to be receiving significant c旭ini､
ca旭 benefit from 旭ong､acting pasireotideq demonstrated acceptab旭e 
to旭erabi旭ity of pasireotide during the core studyq and provided con､
sent to participate in the extensions
ゴsゴ科|科Study design
During the core studyp adu旭ts with confirmed CD and mUFC of 
ゲsズ､ズsグ ┌ ULN were randomized to doub旭e､b旭ind pasireotide ゲグ or 
ザグ mg every ゴ芦 daysq dose titration was permitted based on effi､
cacy｠to旭erabi旭itys11 Patients who entered the extension continued 
旭ong､acting pasireotide ｪwithout interruptionｫ at the same dose that 
they received at month ゲゴs Pasireotide dose cou旭d be increased ｪズ to 
ゲグ mgp ゲグ to ゴグ mgp ザグ to ジグ mg every ゴ芦 daysｫ if mUFC ┒ ゲsグ ┌ ULNp 
providing there was an interva旭 of ┕ザ months since 旭ast increases 
Dose reductions were permitted at any time for to旭erabi旭ity ｪ旭owest 
permitted doser ズ mg every ゴ芦 daysｫs
During the extensionp patients received 旭ong､acting pasir､
eotide for ゲゴ monthsp at which point they continued in the study 
unti旭 an option was avai旭ab旭e to transit to a separate open､旭abe旭p 
旭ong､term safety study of 旭ong､acting pasireotide ｪc旭inica旭tria旭ssgovr 
NCTグゲゼゾジゼゾザq resu旭ts not presentedｫp which occurred once the 
旭ast ongoing patient had received ゲゴ months of treatment during 
the extensions Patients who had received an additiona旭 ┕ゲゴ months 
of treatment after the ゲゴ､month core phase and had the option to 
enter the separate open､旭abe旭p 旭ong､term safety study were consid､
ered to have comp旭eted the extensions The study ended once the 
旭ast patient had received ゲゴ months of treatment during the exten､
sionp and a旭旭 patients had either transited to the 旭ong､term safety 
study or discontinued treatments
ゴsザ科|科Assessments and outcomes 
during the extension
Prespecified outcomes of the extension inc旭uded the fo旭旭owingr 
changes in mUFCp p旭asma ACTHp and morning serum and 旭ate､night 
sa旭ivary cortiso旭 ｪLNSCｫq proportion of patients with contro旭旭ed 
ｪ└ULNｫ or partia旭旭y contro旭旭ed ｪ┒ULN and ┕ズグ鯵 reduction from 
base旭ineｫ mUFCq change in pituitary tumour vo旭umep c旭inica旭 signs of 
hypercortiso旭ism and hea旭th､re旭ated QoL ｪCushingｷs qua旭ity､of､旭ife 
questionnaire ｬCushingQoLｭｫq and safety and to旭erabi旭ity of 旭ong､act､
ing pasireotides
During the extensionp the fo旭旭owing parameters were monitored 
at ザ､month interva旭sr c旭inica旭 signs ｪsysto旭ic b旭ood pressure ｬSBPｭ and 
diasto旭ic b旭ood pressure ｬDBPｭp body mass index ｬBMIｭ and waist 
Conclusions: Long､acting pasireotide provided sustained biochemica旭 and c旭inica旭 im､
provementsp with no new safety signa旭s emergingp supporting its use as an effective 
旭ong､term therapy for CDs
K E Y W O R D S
Cushing syndromep Cushingｷs diseasep extensionp hypercortiso旭ismp pasireotidep Phase IIIp 
pituitary
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circumferenceｫp mUFCp morning serum cortiso旭p LNSC and p旭asma 
ACTHs Bone minera旭 density ｪBMDq 旭eft tota旭 hip and 旭umbar spine 
ｬLゲ､Lジｭｫ was measured at 葦､month interva旭s by Lunar or Ho旭ogic 
dua旭､energy X､ray absorptiometry ｪDXAｫ instrumentss Patients were 
scanned on the same DXA instrument for the duration of the studys 
Pituitary tumour vo旭ume was measured at 葦､month interva旭s by 
magnetic resonance imaging ｪMRIｫ and assessed by a centra旭 readers
Safety was assessed by monitoring adverse events ｪAEsｫs AEs 
were defined using the Medica旭 Dictionary for Regu旭atory Activities 
version ゲ芦sゲ and graded according to Common Termino旭ogy Criteria 
for Adverse Events version ザsグs Laboratory assessmentsp inc旭uding 
haemato旭ogica旭｠b旭ood biochemica旭 measurements ｪfasting p旭asma 
g旭ucose ｬFPGｭp g旭ycated haemog旭obin ｬHbA1cｭp thyroid and 旭iver func､
tion testsｫp vita旭 signsp ga旭旭b旭adder examinations and e旭ectrocardio､
gramsp were assessed as described previous旭ys11
ゴsジ科|科Statistica旭 methods
Efficacy and safety data are presented for patients who entered 
the extensions Ana旭yses were performed once a旭旭 patients had com､
p旭eted the extension or discontinued treatments Morning serum cor､
tiso旭p LNSCp morning p旭asma ACTHp mUFC and c旭inica旭 signs were 
ana旭ysed descriptive旭ys Actua旭｠percentage changes were ca旭cu旭ated 
from core study base旭ine ｪbefore pasireotide initiationｫp and from ex､
tension base旭ine ｪat end of core study ｬmonth ゲゴｭｫ for patients with 
eva旭uab旭e assessments at core｠extension base旭ine and the 旭ater time 
points For the proportions of contro旭旭ed and partia旭旭y contro旭旭ed re､
spondersp two､sided ゾズ鯵 confidence interva旭s ｪCIsｫ were ca旭cu旭ateds 
Efficacy data are presented up to month ザ葦 and at each patientｷs 
旭ast avai旭ab旭e assessments Safety data are presented during the core 
study ｪup to month ゲゴｫ and extension ｪafter month ゲゴ unti旭 study 
endｫs Definitions of diabetic status ｪdiabeticp prediabetic and normo､
g旭ycaemicｫ are inc旭uded in the Appendix Sゲs
ザ科 |科RESULTS
ザsゲ科|科Study popu旭ation
Eighty､one of ゲズグ patients ｪズジsグ鯵ｫ who were enro旭旭ed in the core 
study entered the extensions Thirty､nine ｪジ芦sゲ鯵ｫ patients comp旭eted 
the extension ｪie received ┕ ゲゴ monthsv treatment during the exten､
sion and had opportunity to enter a separate 旭ong､term pasireotide 
safety studyq Figure ゲｫq each of these patients opted to enro旭 in the 
separate 旭ong､term safety study ｪresu旭ts wi旭旭 be pub旭ished sepa､
rate旭yｫs The remaining ジゴ ｪズゲsゾ鯵ｫ patients discontinued 旭ong､acting 
pasireotide during the extensionr ゴズ ｪザグsゾ鯵ｫ discontinued prior to 
month ゴジ and ゲゼ ｪゴゲsグ鯵ｫ discontinued after month ゴジs The most 
common reasons for discontinuation during the extension phase 
were consent withdrawa旭 ｪゲ葦sグ鯵ｫp unsatisfactory therapeutic effect 
ｪゲジs芦鯵ｫ and AEs ｪゾsゾ鯵ｫs
Median duration of pasireotide exposure from study start unti旭 
end of extension was ゴザsゾ months ｪranger ゲゴsグ､ズズsザｫs At extension 
F I G U R E  ゲ 科 Patient dispositions ｰReasons for not entering the extension were not recordedq The death occurred ゲ葦 d after the ゲ葦th 
injection and was not suspected by the treating physician to be re旭ated to pasireotide11; Patients were considered to have comp旭eted 
the extension if both of the fo旭旭owing criteria were metr they had received an additiona旭 ┕ゲゴ mo of treatment during the extensionq and 
the core study had been unb旭indedp which occurred once a旭旭 ゲズグ patients who were enro旭旭ed in the core study had reached month ゲゴ or 
discontinued treatments The AEs 旭eading to discontinuation in 芦 patients during the extension phase were as fo旭旭owsr diabetes me旭旭itusp 
n ┎ ゴq hyperg旭ycaemiap n ┎ ザ ｪone of these patients a旭so had increased gamma､g旭utamy旭transferaseｫq hyperka旭aemiap n ┎ ゲq endometria旭 
cancerp n ┎ ゲq and acute cho旭ecystitisp cho旭e旭ithiasisp e旭evated 旭iver enzymesp bi旭irubin increasedp oedematous pancreatitis and ascitesp n ┎ ゲ 
ｬCo旭our figure can be viewed at wi旭eyon旭ine旭ibraryscomｭ
Entered core study (n = 150)
Completed 12-month core study (n = 104)
Entered extension study (n = 81) Did not enter extension study (n = 23)*
Completed extension study (n = 39)‡
Discontinued during the extension, n = 42
 Consent withdrawal, n = 13
 Unsatisfactory therapeutic effect, n = 12
 Adverse events, n = 8
 Administrative problems, n = 4 
 Abnormal laboratory values, n = 3
 Protocol deviation, n = 1
 Death (cardiorespiratory failure), n = 1†
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startp 旭ong､acting pasireotide was administered at a dose of ズp ゲグp ザグ 
and ジグ mg every ゴ芦 days in 葦p ゲズp ゴグ and ジグ patientsp respective旭ys 
During the extensionp ゲゴ ｪゲジs芦鯵ｫ patients had ┕ゲ dose 旭eve旭 increase 
compared with the month ゲゴ doses
Tab旭e ゲ shows the characteristics at core and extension base旭ine 
for the 芦ゲ patients who entered the extensions
ザsゴ科|科Long､term efficacy
ザsゴsゲ科|科Change in mUFC and other biochemica旭 
markers of CD
At extension startp ジゴ ｪズゲsゾ鯵ｫ patients had contro旭旭ed mUFC 
ｪ└ULNｫs E旭even ｪゲザs葦鯵ｫ patients had partia旭旭y contro旭旭ed mUFC 
ｪ┒ULN but ┕ズグ鯵 decrease from core base旭ineｫp and ゴ芦 ｪザジs葦鯵ｫ had 
uncontro旭旭ed mUFC ｪ┒ULN and ┑ズグ鯵 decrease from core base旭ineｫ 
but were considered to have been receiving c旭inica旭 benefit from 
pasireotide treatments Most patients ｪゼズsグ鯵q n ┎ ゴゲ｠ゴ芦ｫ with un､
contro旭旭ed mUFC at extension had mUFC └ ULN on ┕ゲ visit during 
the core studys
Overa旭旭p ザ芦｠芦ゲ ｪジ葦sゾ鯵ｫ patients had contro旭旭ed mUFC at month 
ゴジ ｪafter ゲゴ months of treatment during the extensionｫs The propor､
tion of patients with contro旭旭ed or partia旭旭y contro旭旭ed mUFC 旭eve旭s 
was stab旭e from extension base旭ine to month ゴジ ｪFigure Sゲｫs Of the 
ジゴ patients with contro旭旭ed mUFC at extension base旭inep ゴゼ ｪ葦ジsザ鯵ｫ 
had contro旭旭ed mUFC at month ゴジp two ｪジs芦鯵ｫ had partia旭旭y con､
tro旭旭ed mUFCp and three ｪゼsゲ鯵ｫ had uncontro旭旭ed mUFCq ゲグ ｪゴザs芦鯵ｫ 
had discontinued or did not have an mUFC assessment at month ゴジs 
E旭even of ザゾ ｪゴ芦sゴ鯵ｫ patients with mUFC ┒ ULN at extension base､
旭ine had contro旭旭ed mUFC at month ゴジq each of these patients had 
mUFC └ ULN on ┕ゲ visit during the core studys
Of patients who received ザ葦 monthsv treatmentp ゲザ｠ゲ芦 ｪゼゴsゴ鯵ｫ 
had contro旭旭ed mUFC at this time points At the time of each patientｷs 
旭ast avai旭ab旭e assessmentp ジザ｠芦ゲ ｪズザsゲ鯵ｫ patients were contro旭旭edp 
ゲ葦｠芦ゲ ｪゲゾs芦鯵ｫ were partia旭旭y contro旭旭ed and ゴゴ｠芦ゲ ｪゴゼsゴ鯵ｫ were 
uncontro旭旭eds
For patients with eva旭uab旭e assessmentsp median mUFC 旭eve旭s 
remained within the norma旭 range ｪゲズsゾ､ゲ葦葦sズ nmo旭｠ゴジ hｫ from ex､
tension base旭ine up to month ザ葦 ｪFigure ゴｫs For the subset of patients 
who received ┕ゲゴ and ┕ゴジ monthsv treatment during the extensionp 
median mUFC 旭eve旭s remained within the norma旭 range from exten､
sion base旭ine up to these time pointss Median ｪrangeｫ change in mUFC 
from start of pasireotide treatment was ┋ゲ芦グsザ nmo旭｠ゴジ h ｪ┋ゲズゴグsグp 
葦葦ゼsゼq n ┎ 芦ゲ ｬ┋ズゲsゾ鯵 changeｭｫ at month ゲゴp ┋ゴザ葦sジ nmo旭｠ゴジ h 
ｪ┋ゲズジゲs芦p ゲゲグゾsザq n ┎ ズ芦 ｬ┋葦ジsゲ鯵ｭｫ at month ゴジp and ┋ゴ葦ゼsゴ nmo旭｠ゴジ h 
ｪ┋ズジザsグp ┋ゴゲsゲq n ┎ ゲ芦 ｬ┋葦芦sザ鯵ｭｫ at month ザ葦s Median ｪrangeｫ change 
in mUFC from extension base旭ine to 旭ast avai旭ab旭e assessment was 
┋ゼsゼ nmo旭｠ゴジ h ｪ┋葦ズゲsゴp 葦葦ゼsザq n ┎ ゼ芦 ｬ┋ズsゾ鯵 changeｭｫs
Median 旭eve旭s of morning p旭asma ACTHp morning serum corti､
so旭 and LNSC were be旭ow core base旭ine 旭eve旭s at each ザ､month旭y 
assessment during the extension ｪFigure ゴ and Appendix Sゲｫp with 
旭eve旭s within the norma旭 range for p旭asma ACTH and morning serum 
cortiso旭 at most time pointss Median LNSC 旭eve旭s decreased from 
ゴs葦 ┌ ULN ｪn ┎ ゼゴｫ at core base旭ine to ゴsグ ┌ ULN ｪn ┎ ゼゲｫ at extension 
base旭inep ゲsジ ┌ ULN ｪn ┎ ズズｫ at month ゴジ and ゲsザ ┌ ULN ｪn ┎ ゲ芦ｫ at 
month ザ葦s
ザsゴsゴ科|科Changes in pituitary tumour vo旭ume
Thirty､four ｪジゴsグ鯵ｫ and ゴ葦 ｪザゴsゲ鯵ｫ patients had a measurab旭e micro､
adenoma or macroadenomap respective旭yp on MRI at start of pasire､
otide treatmentq an adenoma was not visib旭e in ゲゾ ｪゴザsズ鯵ｫ patientss 
Of patients with a measurab旭e adenoma at core base旭ine and month 
ゴジ ｪn ┎ ザズｫp 芦ズsゼ鯵 had a ┕ゴグ鯵 reduction ｪn ┎ ゲゴq ザジsザ鯵ｫ or ┑ゴグ鯵 
change ｪn ┎ ゲ芦q ズゲsジ鯵ｫ in tumour vo旭ume between these time points 
ｪTab旭e Sゲｫs No patient with a macroadenoma at study base旭ine had a 
┕ゴグ鯵 increase in tumour vo旭ume at month ゴジ or ザ葦s
ザsゴsザ科|科Change in c旭inica旭 signs of 
hypercortisolism and health-related QoL
Improvements in median SBPp DBPp BMI and waist circumference 
were sustained during the extension ｪFigure ザｫs For the 芦ゲ patients 
TA B L E  ゲ 科 Summary of base旭ine characteristics for patients who 






Mean agep years ｪSDｫ ザゾsゼ ｪゲゴs芦ｫ ジグsゼ ｪゲゴs芦ｫ
Fema旭esp n ｪ鯵ｫ 葦ゲ ｪゼズsザｫ 葦ゲ ｪゼズsザｫ
Median time since diagnosisp 
months ｪIQRｫ
ゴ葦sゾ ｪゾsザ､葦ズsゾｫ ザゼsゾ ｪゴグsズ､ゼゼsグｫ
Pituitary adenomap n ｪ鯵ｫｰ稼
Nonvisib旭e adenoma ゲゾ ｪゴザsズｫ ゲゼ ｪゴゲsグｫ
Microadenoma ザジ ｪジゴsグｫ ジゲ ｪズグs葦ｫ
Macroadenoma ゴ葦 ｪザゴsゲｫ ゲゼ ｪゴゲsグｫ
Missing ゴ ｪゴsズｫ 葦 ｪゼsジｫ
Base旭ine mUFCp ┌ ULN
Mean ｪSDｫ ゴs葦 ｪゲsズｫ ゲsジ ｪゲsザｫ
Median ｪIQRｫ ゴsザ ｪゲsズ､ザsジｫ ゲsグ ｪグsゼ､ゲs芦ｫ
Previous treatmentp n ｪ鯵ｫ
Previous pituitary surgery 葦ゼ ｪ芦ゴsゼｫ 葦ゼ ｪ芦ゴsゼｫ
Medica旭 therapy ザゴ ｪザゾsズｫ 芦ゲ ｪゲググｫ
Diabetic statusp n ｪ鯵ｫ稼
Norma旭 g旭ucose to旭erance ザズ ｪジザsゴｫ 葦 ｪゼsジｫ
Prediabetic ゲジ ｪゲゼsザｫ ゾ ｪゲゲsゲｫ
Diabetic ザゴ ｪザゾsズｫ 葦葦 ｪ芦ゲsズｫ
Abbreviationsr IQRp interquarti旭e rangeq SDp standard deviations
ｰPituitary adenoma size defined according to maximum tumour diame､
ter ｪmicroadenoma ┒グ･┑ゲグ mmq macroadenoma ┕ゲグ mmｫs 
Diabetic status defined as fo旭旭owsr diabeticp patients with 
HbA1c ┕ 葦sズ鯵p FPG ┕ ゲゴ葦 mg｠dLp prior history of diabetes me旭旭itusp or 
receiving antidiabetic medicationq prediabeticp patients not qua旭ifying as 
diabetic and FPG ┒ゲググ･┑ゲゴ葦 mg｠dL or HbA1c ┒ズsゼ･┑葦sズ鯵q and norma旭 
g旭ucose to旭erancep patients not qua旭ifying as diabetic or prediabetics 
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who entered the extension phasep median ｪrangeｫ changes from start 
of treatment to the end of the core study ｪmonth ゲゴｫ were as fo旭旭owsr 
SBPp ┋ジsグ mm Hg ｪ┋ジズsザp ゴゼsザq n ┎ 芦グｫq DBPp ┋ゴsグ mm Hg ｪ┋ジ芦sグp 
ゲゾsザq n ┎ 芦グｫq waist circumferencep ┋ズsグ cm ｪ┋ザ芦sグp ザジsグq n ┎ ゼズｫq 
and BMIp ┋ゲsゾ kg｠m2 ｪ┋ゲゲsゴp ザsズq n ┎ 芦グｫs Median ｪrangeｫ changes 
from extension base旭ine to 旭ast avai旭ab旭e assessment were as fo旭旭owsr 
SBPp ゴsゼ mm Hg ｪ┋ジゲsゼp ゴゼsザq n ┎ ゼゾｫq DBPp グsグ mm Hg ｪ┋ゴゴsグp ゴゴsグq 
n ┎ ゼゾｫq waist circumferencep ゲsグ cm ｪ┋ゲザsグp ゴゲsグq n ┎ ゼゼｫq and BMIp 
グsゲ kg｠m2 ｪ┋ズsゼp ジsゲq n ┎ ゼゾｫs
Forty､five ｪズズs葦鯵ｫ patients were receiving antihypertensive med､
ication at extension base旭ines Five patients received ┕ゲ additiona旭 
agentp and two initiated antihypertensive medication during the 
extensions Converse旭yp five patients who were on antihypertensive 
medication at extension base旭ine were receiving ┕ゲ fewer agent at 
their 旭ast visitp one of whom was not receiving any b旭ood pressure･
旭owering medications
There were no c旭ear changes in b旭ood 旭ipid 旭eve旭s or BMD ｪ旭eft 
tota旭 hip and 旭umbar spineｫ over ザ葦 monthsv treatment ｪTab旭e Sゴｫs In 
tota旭p ゴゼ ｪザザsザ鯵ｫ patients were receiving 旭ipid､旭owering medication 
at extension base旭inep none of whom had an increase in the number 
of prescribed medications during the extensions Four additiona旭 pa､
tients started 旭ipid､旭owering drugs during the extensions
Median ｪrangeｫ CushingQoL score was ジゲsゼ ｪ葦sザp 芦ゲsザq n ┎ ゼゾｫ 
prior to starting pasireotides Median ｪrangeｫ CushingQoL score im､
proved from core study base旭ine by ゾsジ points ｪ┋ザゲsザp ズ葦sザq n ┎ ゼ芦ｫ 
at month ゲゴp 芦sザ points ｪ┋ザゲsザp ゴゾsゴq n ┎ ズゼｫ at month ゴジp and ゲグsジ 
F I G U R E  ゴ 科 Median mUFCp ACTHp serum cortiso旭 and LNSC over timep by duration of pasireotide treatments Continuous 旭ines represent 
data co旭旭ected during the extensionq dashed 旭ines represent data co旭旭ected during the core study for patients who were 旭ater enro旭旭ed in the 
extensions Horizonta旭 reference 旭ines represent the ULN range for mUFC ｪゲ葦葦sズ nmo旭｠ゴジ hｫp morning p旭asma ACTH ｪジズsジ ng｠Lｫp morning 
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57 28 197076 59 35 238180 77
7585 59 5955 57 55
91819181 19 1918 19 17 19 18
55 27 186772 60 35 227472 71
5515 54 5753 57 58
81717151 16 1916 14 18 18 18
Duration of long-acting 
pasireotide exposure
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points ｪ┋ゴゼsゲp ザゲsザq n ┎ ゲゼｫ at month ザ葦s Median ｪrangeｫ change in 
CushingQoL score from extension base旭ine to 旭ast observed va旭ue 
was ┋ゴsゲ points ｪ┋ズゴsゲp ゴゼsゲq n ┎ ゼ葦ｫs
ザsザ科|科Long､term safety
Most patients ｪゼジq ゾゲsジ鯵ｫ experienced one or more AEs during the 
extensions Grade ザ｠ジ events were reported in ザゲ ｪザ芦sザ鯵ｫ patients 
ｪTab旭e ゴｫs Hyperg旭ycaemia ｪゴザsズ鯵ｫ was the most common旭y reported 
AE during the extensions When a旭旭 AE terms re旭ated to hyperg旭ycaemia 
were groupedp ザゴ ｪザゾsズ鯵ｫ patients experienced any hyperg旭ycaemia､
re旭ated AE during the extensionp which 旭ed to discontinuation in three 
patientss Fifty､eight ｪゼゲs葦鯵ｫ patients experienced a hyperg旭ycae､
mia､re旭ated AE during the ゲゴ､month core studys Other common AEs 
ｪ┕ゲズ鯵 of patientsｫ during the extension were nasopharyngitis ｪゲゾs芦鯵ｫp 
cho旭e旭ithiasis ｪゲ芦sズ鯵ｫ and diarrhoea ｪゲゼsザ鯵ｫs Except for nasopharyn､
gitisp these AEs occurred in fewer patients during the extension than 
the core study ｪTab旭e ゴｫs Gastrointestina旭 AEs were a旭so 旭ess common 
during the extension than the core studyr diarrhoea ｪゲゼsザ鯵 vs ザジs葦鯵ｫp 
nausea ｪゾsゾ鯵 vs ゴゴsゴ鯵ｫ and abdomina旭 pain ｪゴsズ鯵 vs ゲジs芦鯵ｫs
Sixteen ｪゲゾs芦鯵ｫ patients experienced a ga旭旭b旭adder｠bi旭iary tract･re､
旭ated AE during the extensionp most common旭y cho旭e旭ithiasis ｪn ┎ ゲズｫs 
One patient discontinued treatment because of cho旭e旭ithiasisp in､
creased b旭ood bi旭irubinp and acute cho旭ecystitiss Three ｪザsゼ鯵ｫ patients 
experienced bradycardia､re旭ated AEs during the extensionp none of 
which 旭ed to discontinuations Liver safety･re旭ated AEs occurred in nine 
ｪゲゲsゲ鯵ｫ patientsp with four discontinuing treatmentr increased hepatic 
enzymes with concomitant AEs of acute pancreatitis and acute cho､
旭ecystitisp n ┎ ゲq increased hepatic enzymesp n ┎ ゲ ｪdrug､induced 旭iver 
injury not objectified in c旭inica旭 or subsequent 旭aboratory findingsｫq in､
creased gamma､g旭utamy旭transferase with a concomitant AE of hyper､
g旭ycaemiap n ┎ ゲq and increased a旭anine aminotransferasep n ┎ ゲs
One patient died from cardiac fai旭ure during the extensions This 
death was previous旭y reported as part of the core study ana旭ysisp11 as 
the patient died before unb旭inding of the core studys The death was 
not suspected to be study drug re旭ateds
F I G U R E  ザ 科 Median SBPp DBPp waist circumference and BMIp by duration of pasireotide treatments Continuous 旭ines represent data 
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For patients who entered the extensionp mean HbA1c and FPG 
旭eve旭s increased from core base旭ine to month ゲゴ ｪextension base､
旭ineｫs Mean HbA1c and FPG 旭eve旭s were stab旭e during the extension 
ｪFigure ジｫs Mean ｪゾズ鯵 CIｫ changes in HbA1c and FPG from extension 
base旭ine to 旭ast observed va旭ue were グsグ鯵 ｪ┋グsゴp グsゴq n ┎ ゼゼｫ and 
┋葦s葦 mg｠dL ｪ┋ゲジsズp ゲsザq n ┎ ゼ芦ｫp respective旭ys
At extension base旭inep 葦葦 ｪ芦ゲsズ鯵ｫp nine ｪゲゲsゲ鯵ｫ and six ｪゼsジ鯵ｫ pa､
tients were c旭assified as diabeticp prediabetic and normog旭ycaemics At 
旭ast avai旭ab旭e assessmentp no patients had shifted from normog旭ycae､
mic to prediabetic｠diabeticp whi旭e six ｪ葦葦sゼ鯵ｫ had shifted from predia､
betic to diabetics Twe旭ve patients ｪゲジs芦鯵ｫ had HbA1c ┕ 芦鯵 at their 旭ast 
assessmentq nine of these patients had HbA1c ┕ 芦鯵 at extension base､
旭ines One patient had shifted from prediabetic to normog旭ycaemic at 
their 旭ast assessments Overa旭旭p ズグ｠芦ゲ ｪ葦ゲsゼ鯵ｫ patients were receiv､
ing antidiabetic medication at extension base旭ine ｪone medicationp 
n ┎ ゴゲq two medicationsp n ┎ ゲジq three or more medicationsp n ┎ ゲズｫs At 
旭ast assessmentp an increase in antidiabetic medications was reported 
in ゲグ｠ザズ ｪゴ芦s葦鯵ｫ patientss Eight of ザゲ ｪゴズs芦鯵ｫ patients who were not 
receiving antidiabetic drugs at month ゲゴ were being treated with 
antidiabetic medication at their 旭ast assessments Seventeen ｪゴゲsグ鯵ｫ 
patients were receiving insu旭in at extension base旭ineq a further ゲグ 
ｪゲゴsザ鯵ｫ patients started insu旭in therapy during the extensions
ジ科 |科DISCUSSION
In this 旭argep prospectivep extension studyp patients were treated 
with 旭ong､acting pasireotide for a median of ゴ yearsp a旭旭owing robust 
interpretation of its 旭ong､term efficacy and safetys Long､acting pa､
sireotide provided sustained biochemica旭 improvements and c旭ini､
ca旭 benefit in a significant proportion of patients with CD and was 
genera旭旭y we旭旭 to旭eratedp with no new safety signa旭s emerging over 
旭ong､term treatments
Achieving and maintaining norma旭 cortiso旭 旭eve旭s is a key treat､
ment goa旭 for patients with CD in order to prevent or a旭旭eviate the 
c旭inica旭 signs and comp旭ications of hypercortiso旭ism and improve 
旭ife expectancys8 A旭most ha旭f ｪジゼ鯵ｫ of patients who entered this 
extension study had contro旭旭ed mUFC after ゴ years of 旭ong､acting 
pasireotide treatmentq ゴズ鯵 ｪn ┎ ザ芦｠ゲズグｫ of patients who were en､
ro旭旭ed in the core study had contro旭旭ed mUFC at month ゴジs Base旭ine 
characteristics for patients who entered this extension study were 
simi旭ar to those reported previous旭y for a旭旭 patients who participated 
in the initia旭 core phase of the study ｪN ┎ ゲズグｫs11 Patients cou旭d 
continue receiving pasireotide beyond month ゴジ unti旭 there was an 
option to enter a separate 旭ong､term study of pasireotides Over two､
thirds ｪゼゴsゴ鯵q n ┎ ゲザ｠ゲ芦ｫ of patients who were sti旭旭 participating in 
the extension at month ザ葦 had contro旭旭ed mUFC at this time points 
Furthermorep over ha旭f ｪズザ鯵ｫ of patients who entered the extension 
had a norma旭 mUFC 旭eve旭 at their 旭ast assessmentp which was mar､
gina旭旭y higher than the proportion of responders at extension starts 
These resu旭ts support the 旭ong､term efficacy of pasireotide and 
are consistent with findings from a Phase III studyp in which 葦ゾ鯵 
ｪn ┎ ゲゲ｠ゲ葦ｫ of ongoing patients had contro旭旭ed mUFC after ズ years 
of twice､dai旭yp subcutaneous pasireotide therapysゲジpゲズ Improvements 
in median mUFCp morning serum cortiso旭 and LNSC 旭eve旭s were 
reported overa旭旭 and for patients who received ┕ゴ or ┕ザ years of 
AEp n ｪ鯵ｫ
Months 0-12 After month 12
All grades Grade 3/4 All grades Grade 3/4
Total 80 (98.8) 33 (40.7) 74 (91.4) 31 (38.3)
Hyperg旭ycaemia ザゴ ｪザゾsズｫ ジ ｪジsゾｫ ゲゾ ｪゴザsズｫ ザ ｪザsゼｫ
Nasopharyngitis ゲジ ｪゲゼsザｫ 0 ゲ葦 ｪゲゾs芦ｫ 0
Cho旭e旭ithiasis ゴザ ｪゴ芦sジｫ ゲ ｪゲsゴｫ ゲズ ｪゲ芦sズｫ ゴ ｪゴsズｫ
Diarrhoea ゴ芦 ｪザジs葦ｫ 0 ゲジ ｪゲゼsザｫ 0
Urinary tract 
infection
葦 ｪゼsジｫ 0 ゲグ ｪゲゴsザｫ 0
Headache ゲゲ ｪゲザs葦ｫ 0 ゾ ｪゲゲsゲｫ 0
Diabetes me旭旭itus ゲズ ｪゲ芦sズｫ ゼ ｪ芦s葦ｫ 芦 ｪゾsゾｫ ジ ｪジsゾｫ
Nausea ゲ芦 ｪゴゴsゴｫ 0 芦 ｪゾsゾｫ 0
Hypog旭ycaemia ゲグ ｪゲゴsザｫ ゴ ｪゴsズｫ 芦 ｪゾsゾｫ ゴ ｪゴsズｫ
Fatigue ゲゲ ｪゲザs葦ｫ 0 ゼ ｪ芦s葦ｫ 0
Dizziness ゲゲ ｪゲザs葦ｫ ゲ ｪゲsゴｫ 葦 ｪゼsジｫ 0
Abdomina旭 pain ゲゴ ｪゲジs芦ｫ 0 ゴ ｪゴsズｫ ゲ ｪゲsゴｫ
Inf旭uenza ゲゲ ｪゲザs葦ｫ 0 ズ ｪ葦sゴｫ 0
Oedema periphera旭 ゲグ ｪゲゴsザｫ 0 ズ ｪ葦sゴｫ 0
Note: AEs are sorted in descending order of events during the extensions Patients who experienced 
an AE during the core study ｪmonths グ､ゲゴｫ and the extension ｪafter month ゲゴｫ are counted in both 
co旭umnss
TA B L E  ゴ 科 AEs ｪ┕ゲグ鯵 of patients during 
the core or extension phaseｫp regard旭ess of 
drug re旭ationshipp in the 芦ゲ patients who 
entered the extension
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treatments Un旭ike mUFC and morning serum cortiso旭p median LNSC 
remained ┒ULN during the extensions Additiona旭 studies are needed 
to examine the effect of cortiso旭､旭owering therapies on sa旭ivary cor､
tiso旭 and the ro旭e of LNSC in monitoring medica旭 treatment responses
Cardiovascu旭ar disease is the 旭eading cause of death in patients 
with CDs16 Consequences of cortiso旭 excess that can contribute to 
cardiovascu旭ar disease inc旭ude hypertensionp trunca旭 obesityp impaired 
g旭ucose to旭erancep insu旭in resistancep dys旭ipidaemia and hypercoagu旭a､
bi旭itys17 In our studyp improvements in b旭ood pressurep BMI and waist 
circumference were maintained for up to ザ years of pasireotide treat､
ments Such improvements may confer a reduction in morta旭ity riskp 
given that sma旭旭 reductions in b旭ood pressure can significant旭y reduce 
the risk of cardiovascu旭ar events in patients with hypertensions18 
Contrary to previous reportsp we did not observe any consistent 
changes in cho旭estero旭 or trig旭ycerides during our studysゲ芦pゲゾ
It is important to note that concomitant medications were 
a旭旭owed during this studyp which cou旭d have contributed to the 
observed changes in c旭inica旭 signs over times Persistent hypercor､
tiso旭ism is associated with progressive bone degradation resu旭ting 
in increased fracture risk for patients with CDs20 Encouraging旭yp 
BMD was stab旭e throughout ザ葦 months of pasireotide treatmentp 
a旭though additiona旭 studies are warranted to confirm the effects of 
pasireotide on the prevention｠reversa旭 of bone deterioration in pa､
tients with CDs
Hypercortiso旭ism and its c旭inica旭 effects detrimenta旭旭y impact 
on QoLq the effects often persist after the reso旭ution of hypercor､
tiso旭isms21 Patients who participated in the current extension had 
significant旭y impaired QoL ｪCushingQoL scorep ジゲsゼ pointsｫ prior 
to starting treatment with 旭ong､acting pasireotides Important旭yp 
CushingQoL score improved from base旭ine over ザ years of treat､
mentp potentia旭旭y ref旭ecting the improvements in c旭inica旭 signs of hy､
percortiso旭ism during pasireotide treatments
Pituitary tumour vo旭ume decreased or remained stab旭e in most 
patients during 旭ong､term treatment with pasireotidep consistent 
with previous reportssゴゴ､ゴズ Given its tumour､shrinkage effectsp it 
has been proposed that pasireotide may be particu旭ar旭y beneficia旭 
in patients with a c旭inica旭旭y re旭evant tumour mass and｠or tumour 
progressionsゾpゲグpゴ葦 This assertion is supported by our findings that 
a旭most ha旭f ｪジ葦鯵q n ┎ 葦｠ゲザｫ of patients with a macroadenoma before 
initiation of pasireotide treatment had a significant ｪ┕ゴグ鯵 changeｫ 
decrease in tumour vo旭ume by month ゴジp with the remainder exhib､
iting stab旭e tumour sizes
The safety profi旭e of 旭ong､acting pasireotide during this extension 
was simi旭ar to that during the core studyp with no new safety signa旭s 
emergings AEs were genera旭旭y mi旭d｠moderate and occurred 旭ess fre､
quent旭y in the extension than in the first ゲゴ months of treatments The 
旭ower rate of AEs in the extension phase than in the core study may be 
exp旭ained by the ear旭y onset and effective management of side effects 
during pasireotide treatmentp whi旭e patients who to旭erated pasireotide 
may have been more 旭ike旭y to continue into the extension phases These 
findings are simi旭ar to those of a previous prospective study of subcuta､
neous twice､dai旭y pasireotidep in which AEs re旭ated to hyperg旭ycaemiap 
旭iver safetyp the ga旭旭b旭adder and bradycardia tended to emerge during 
the first 葦 months of treatment and did not usua旭旭y worsen over ズ yearsv 
treatments14
According to the American Diabetes Association and European 
Association for the Study of Diabetesp g旭ycaemic targets shou旭d be 
individua旭ized based on key patient characteristicss As suchp whi旭e 
an HbA1c 旭eve旭 of ┑ゼ鯵 represents a reasonab旭e goa旭 for many adu旭tsp 
旭ess stringent targets ｪsuch as ┑芦鯵ｫ are appropriate in some patientsp 
such as those with extensive comorbid conditionssゴゼpゴ芦 In our studyp 
mean HbA1c and FPG 旭eve旭s were stab旭eq mean HbA1c remained 
┑ゼ鯵 over the course of the extensionp and most ｪ芦ズ鯵ｫ patients had 
HbA1c ┑ 芦sグ鯵 at their 旭ast assessments
Initiation and esca旭ation of antidiabetic therapy was at the dis､
cretion of the investigatorq ゴ葦鯵 of patients who were not receiving 
antidiabetic therapy at extension base旭ine were receiving at 旭east 
one agent at their 旭ast assessmentp whi旭e ゴゾ鯵 of patients who were 
a旭ready receiving ゲ､ゴ antidiabetic drugs were receiving at 旭east one 
additiona旭 agents Taken togetherp these findings demonstrate that if 
hyperg旭ycaemia occursp it tends to emerge soon after initiation of 
F I G U R E  ジ 科 Mean ｪSDｫ FPG and HbA1c 旭eve旭s during the 
extension phases Continuous 旭ines represent data co旭旭ected during 
the extensionq dashed 旭ines represent data co旭旭ected during the core 
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pasireotide and can be effective旭y managed in some patients with 
antidiabetic therapys
Few studies have examined the efficacy and safety of 旭ong､term 
treatment with other medica旭 therapies for CDs In a retrospective 
ana旭ysis of ズゲ patients who had received 旭ong､term ｪ┕ゴ yearsｫ ke､
toconazo旭e treatmentp a norma旭 mUFC 旭eve旭 was seen in 葦ズ鯵 of 
patients at their 旭ast avai旭ab旭e assessmentp with c旭inica旭 improve､
ments seen in hypertensionp diabetes and hypoka旭aemias29 One､fifth 
ｪゴグsズ鯵ｫ of patients discontinued treatment because of into旭erances29 
In a retrospective ana旭ysis of metyrapone treatmentp 葦ジ鯵 ｪn ┎ ゾ｠ゲジｫ 
of patients who had an avai旭ab旭e mUFC assessment after ┕葦 months 
of treatment had a norma旭 mUFC 旭eve旭 at their 旭ast avai旭ab旭e as､
sessmentp whi旭e there was a 旭ow incidence ｪゲゲ鯵q n ┎ ジ｠ザ芦ｫ of AEs 
in these patientssザグ In another retrospective studyp ジグ鯵 ｪn ┎ ゴゲ｠ズザｫ 
of patients receiving cabergo旭ine therapy initia旭旭y achieved norma旭 
UFC 旭eve旭sp with treatment escape seen in ザゾ鯵 ｪn ┎ ゼ｠ゲ芦ｫ of patients 
who remained on treatment for ┕ゲゴ monthssザゲ Pub旭ished data on 
mifepristone and osi旭odrostat are 旭imited to shorter durations of 
treatmentsザゴpザザ The choice of medica旭 treatment options shou旭d be 
tai旭ored to the individua旭 c旭inica旭 situationp taking into consideration 
the patientp disease and tumour characteristicss8
ズ科 |科CONCLUSIONS
Patients who entered this extension study exhibited sustained bio､
chemica旭 and c旭inica旭 benefit over ザ years of treatment with 旭ong､
acting pasireotidep which was accompanied by improvements in QoL 
and tumour size contro旭s The 旭ong､term safety profi旭e of pasireotide 
was favourab旭e and consistent with that reported during the first 
ゲゴ months of treatments These data support the use of 旭ong､acting 
pasireotide as an effective 旭ong､term treatment option for some pa､
tients with CDs
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